262. Clinical trials market size, share, growth, analysis report, 2018–2025
[Электронный ресурс] // Grand View Research. – 2018. – Режим доступа:
https://www.grandviewresearch.com/industry-analysis/global-clinical-trials-
market.
263. Concept paper on the development of product–specific guidance on
demonstration of bioequivalence [Электронный ресурс] / European Medicines
Agency.committee for Medical Products of Human use. – 2013. –
Режим
доступа:
www.ema.europa.eu/docs/en_GB/document_library/Scientific_
guideline/2013/07/.
264. Concept paper on the development of a guideline on 5 quality and
equivalence of topical products. EMA/CHMP/QWP/558185/2014 [Электрон-
ный ресурс] / European Medicines Agency.committee for Medical Products
of Human use. – 2014. – Режим доступа: www.ema.europa.eu/en/documents/
scientific-guideline/concept-paper-development-guideline–quality-equivalence-
topical-products_en.pdf.
265.
Cramer, R.D.
Сomparative molecular field analysis (CoMFA). 1.
Effect of shape on binding of steroids to carrier proteins [Текст] / R.D. Cramer,
D.E. Patterson, J.D. Bunce // Journal of the American Chemical Society. – V. 18,
№110. – р. 5959–5967.
266. Cruz–Monteagudo, M. Activity cliffs in drug discovery: Dr Jekyll or Mr
Hyde? [Текст] / M. Cruz-Monteagudo, J. L. Medina-Franco, Y. Perez-Castillo [et
al.] // Drug Discovery Today. – 2014. –V. 19, №8. – р. 1069–1080.
267.
Csermely, P
. The efficiency of multi–target drugs: the network approach
might help drug design [Текст] / P. Csermely //
Trends in Pharmacological
Sciences. – 2005. – V. 26, №4. – р. 178–182.
268.
Dean, P. M
. Molecular Similarity in Drug Design [Текст] / P. M. Dean. –
London: Blackie Academic. – 1995.
269. Developmental Therapeutics Program [Электронный ресурс]. – Режим
доступа: dtp.cancer.gov.
270.
DiMasi, J.A
. Innovation in the pharmaceutical industry: New estimates
of R&D costs [Текст] / J.A. DiMasi, H.G. Grabowski, R.W. Hansen // Journal of
Health Economics. – 2016. – V. 47. – p. 20–23.
271.
Dimova, D
. Advances in Activity Cliff Research [Текст] / D. Dimova,
J. Bajorath // Molecular Informatics. – 2016. – V. 35, №5. – р. 181–191.
272.
Dmitriev, A.V
. Drug–Drug Interaction Prediction using PASS [Текст]
/ A.V. Dmitriev, D.A. Filimonov, A. V.rudik [et al.]// SAR and QSAR in
Environmental Research. – 2019. – V. 30, №9. – р. 655–664.
273. Directive 2001/83/EC of the European Parliament
and of the Council
of 6 November 2001 on the Community code relating to medicinal products
for human use. [Электронный ресурс]. – Режим доступа: eur-lex.europa.eu/
homepage.html.
274. Directive 2010/63/EU of the European Parliament and of the Council of
22Sep2010 on the protection of animals used for scientific purposes [Электрон-
ный ресурс]. – Режим доступа: http://www.europarl.europa.eu/sides/getDoc.
do?type=REPORT&reference=A7-2013-0324&language=EN.
275. DrugBank [Электронный ресурс]. – Режим доступа: www.
drugbank.ca.
Список литературы
375
276. Efficacy Guidelines от International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human Use (ICH) [Электрон-
ный ресурс]. – Режим доступа: www.ich.org/products/guidelines/quality/
article/еfficacy-guidelines.html.
277.
Eleftheriou, P
.
Fragment-based design, docking, synthesis, biological
evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-
5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors [Текст] /
P. Eleftheriou, A. Geronikaki, D. Hadjipavlou-Litina [et al.] // European Journal
of Medicinal Chemistry. –2012. – V. 47, №1. – р. 111–124.
278.
Esposito, E.X
. Methods for applying the quantitative structure–activity
relationship paradigm [Текст] / E.X. Esposito, A.J. Hopfinger, J.D. Madura //
Methods in Molecular Biology. – 2004. – V. 275. – p. 131–214.
279. European Medicines Agency post–authorisation procedural advice
for users of the centralised procedure. EMEA-H-19984/03 Rev. 70.
Human
Medicines Evaluation Division [Текст] / European Medicines Agency. – 2017. –
274 P.
280. FDA Dissolution Database [Электронный ресурс]. – Режим доступа:
http://www.accessdata. fda.gov/scripts/CDER/dissolution.
281. Federal Food, Drug, and Cosmetic Act [as amended through P. L.
116–8, enacted March 08, 2019] [Электронный ресурс]. – Режим доступа:
legcounsel.house.gov/comps/federal%20food,%20drug,%20and%20cosmet-
ic%20act.pdf.
282.
Feher, M.
Property distributions: differences between drugs, natural
products, and molecules from combinatorial chemistry [Текст] / M. Feher,
J.M. Schmidt // Journal of Chemical Information and Computer Sciences. –
2003. – V. 43, №1. – р. 218–227.
283.
Filimonov, D
. Сomputer–aided prediction of biological activity spectra
for chemical compounds: opportunities and limitations [Текст] / D.A. Filimonov,
D.S. Druzhilovskiy, A A. Lagunin [et al.] // Biomedical Chemistry: Research and
Methods. – 2018. – V. 1, №1. – Режим доступа: www.bmc-–rm.org/index.php/
bmcrm/article/view/4.
284.
Filimonov, D
. Chemical similarity assessment through multilevel
neighborhoods of atoms: definition and comparison with the other descriptors
/ D. Filimonov, V. Poroikov, Yu. Borodina [et al.] //
Journal of Chemical
Information and Computer Sciences. – 1999. – V. 39, №4. – р. 666–670.
285.
Filimonov, D.A
. PASS: computerized prediction of biological activity
spectra for chemical substances. In: Bioactive Compound Design: Possibilities
for Industrial Use [Текст]: D.A. Filimonov, V.V. Poroikov. – Oxford: BIOS
Scientific
Publishers, 1996. – p. 47–56.
286.
Filimonov, D.A
. Probabilistic approach in activity prediction [Текст]:
In: Chemoinformatics Approaches to Virtual Screening / D.A. Filimonov,
V.V. Poroikov; edit by A. Varnek, A. Tropsha. – Cambridge (UK): RSC
Publishing, 2008. – p. 182–216.
287.
Filimonov, D.A
. Prediction of the biological activity spectra of organic
compounds using the PASS online web resource / D.A. Filimonov, A.A. Lagunin,
T.A. Gloriozova [et al.]// Chemistry of Heterocyclic Compounds. – 2014. – V. 50,
№3. – р. 444–457.
376
Достарыңызбен бөлісу: